Barbosa C, et al. - Using a health care perspective, researchers employed hepatitis C (HCV)-transmission and disease progression models with cost-effectiveness analysis to examine the cost-effectiveness of HCV therapy in people who inject drugs (PWID), combined with medication-assisted treatment (MAT) and syringe-service programs (SSP), to address the growing HCV epidemic in the United States. This study was conducted in rural Perry County, KY (PC), and urban San Francisco, CA (SF). From Social Networks Among Appalachian People, U Find Out, Urban Health Study, and National HIV Behavioral Surveillance System studies, they collected data on PWID from 1998 to 2015. Three intervention scenarios illustrated: baseline—existing SSP and MAT coverage with HCV screening and therapy with direct-acting antiviral among ex-injectors only as per standard of care; Intervention 1—scale-up of SSP and MAT with no modifications in treatment; and Intervention 2—scale-up as Intervention 1 combined with HCV screening and treatment for current PWID. Data analysis revealed that for reducing hepatitis C burden in the United States, hepatitis C screening and treatment for PWID in combination with medication-assisted treatment and syringe-service programs is a cost-effective strategy.